Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Epix Pharmaceuticals, Inc.
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or Women with a clinical diagnosis of Probable AD
MMSE score 12 to 22 inclusive
Age \>50 and \<90 years
Received at least 4 months of a stable dose of donepezil 10mg QD for AD
Brain CT or MRI scan Consistent with a primary diagnosis of AD within 24 months
Neurological examination without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)
No history or evidence of any other CNS disorder that could be interpreted as a cause of dementia
No diagnosis of vascular dementia
No history of significant psychiatric illness such as schizophrenia or bipolar affective disorder. Subjects with major depressive disorder on a stable dose of an antidepressant for \>6 months may be eligible
No evidence of the following: current vitamin B12 deficiency, positive syphilis serology, positive HIV test, or abnormalities in thyroid function
No cognitive rehabilitation within 6 months of the study
Subject has a regular caregiver willing to attend all study visits
Signed informed consent by the subject (and legal guardian, if applicable)
No history of drug or alcohol abuse
No clinically significant laboratory abnormalities or medical history
No investigational drug within 30 days of Randomization
Cannot receive memantine within 2 months of enrollment
No other prescription acetylcholinesterase inhibitors for AD (other than donepezil) within 4 months of enrollment
No clinically significant ECG abnormalities or cardiac history
No history of uncontrolled seizure disorder within 12 months of enrollment
Cannot be taking MAO inhibitors, bupropion,fluoxetine, paroxetine, quinidine
No history of malignancy within 3 years of randomization
